Historically, neoadjuvant chemotherapy for NSCLC has demonstrated only moderate efficacy, with limited long-term survival benefits (Forde et al., 2022) while the evidence for the efficacy of chemoimmunotherapy, the current standard of care, remains scant in HER2-mutated patients. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.